DMRA

Damora is a clinical-*stage-in-name-only* biopharma: by its own 10-K, it has not yet filed an IND or CTA for its lead candidate. DMR-001 (a mutCALR-targeting antibody for ET and myelofibrosis) is guided to IND/CTA only in mid-2026, with DMR-002 in 2H-2026 and DMR-003 in 2027. Every differentiation claim — best-in-class potency, ~10x activity on Type 2 mutCALR, prolonged half-life — is explicitly preclinical. There is no human efficacy or safety data, no approved product, and (per the revenue history) no revenue in any year FY2021-FY2025. The $5B addressable-market figure is a TAM aspiration, not a forecast.

The headline valuation is a trap. The provided 'P/E 6.1' rests on a diluted EPS of $3.98 that is irreconcilable with a -$210M net loss and -87% ROE — it is a non-comparable artifact of the asset acquisition that exploded shares outstanding +4,460% YoY and the expensing of acquired in-process R&D. You cannot value this company on earnings; it has none in the normal sense. The FY2025 net loss ballooned to -$210M (from -$21M) largely because acquired IPR&D and the Paragon option costs are expensed up front — note operating cash flow was only -$6.73M, so the loss is mostly non-cash. That reconciliation matters, but it doesn't make the stock cheap; it just means the loss isn't the burn rate.